SPY756.10−0.49%QQQ684.00−0.92%BTC/USD73,628.30−0.40%DIA524.23−0.04%GLD365.88+0.19%TLT80.87−0.06%

Maravai LifeSciences Holdings Inc

MRVINASDAQ

Trade with Public

$7.70

-0.16-2.04%

Last update: Nov 11, 4:55 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Maravai LifeSciences (MRVI) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Maravai LifeSciences (MRVI) stock.

Analyst Consensus — 9 Analysts

6Buy

3Hold

# Analysts9

Latest Upgrades and Downgrades for Maravai LifeSciences Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Dan Brennan	PT Raise	Neutral	$3→$8
—	Wells Fargo	Evan Stampler	PT Raise	Overweight	$6→$7
—	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$5→$6
—	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$4→$5
—	Craig-Hallum	Christian Schwab	PT Cut	Buy	$10→$5
—	RBC Capital	Conor McNamara	PT Cut	Outperform	$7→$5
—	Craig-Hallum	Christian Schwab	PT Cut	Buy	$12→$10
—	Baird	Catherine Schulte	PT Cut	Neutral	$3→$2
—	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$7→$5
—	UBS	Dan Brennan	PT Cut	Neutral	$8→$3
—	B of A Securities	Michael Ryskin	PT Cut	Buy	$9→$8
—	Baird	Catherine Schulte	Downgrade	Outperform→Neutral	$9→$3
—	Goldman Sachs	Matthew Sykes	Downgrade	Neutral→Sell	$7→$4
—	Wolfe Research	Doug Schenkel	Initiate	Peer Perform	—
—	RBC Capital	Conor McNamara	PT Cut	Outperform	$17→$13
—	William Blair	Matt Larew	Downgrade	Outperform→Market Perform	—
—	Baird	Catherine Schulte	PT Cut	Outperform	$10→$9
—	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$8→$7
—	Wells Fargo	Brandon Couillard	Initiate	Overweight	$10
—	RBC Capital	Conor McNamara	Maintained	Outperform	$15

Maravai LifeSciences Holdings Inc

Maravai LifeSciences (MRVI) Stock Price Target 2026

Latest Upgrades and Downgrades for Maravai LifeSciences Stock

Maravai LifeSciences (MRVI) Stock Price Target 2026

Latest Upgrades and Downgrades for Maravai LifeSciences Stock

Analyst Ratings News

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

People Also Watch

People Also Watch

Analyst Ratings News

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

Maravai LifeSciences Holdings Inc

Maravai LifeSciences (MRVI) Stock Price Target 2026

Latest Upgrades and Downgrades for Maravai LifeSciences Stock

Maravai LifeSciences (MRVI) Stock Price Target 2026

Latest Upgrades and Downgrades for Maravai LifeSciences Stock

Analyst Ratings News

PROUBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRORBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

People Also Watch

People Also Watch

Analyst Ratings News

PROUBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRORBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5